What is Vericel?
Vericel Corporation operates at the intersection of biotechnology and advanced manufacturing, specializing in the development and commercialization of patient-specific cell therapies. The company's core focus lies in regenerative medicine, where it utilizes innovative cellular technologies to repair damaged tissues and restore function in patients suffering from complex orthopedic conditions and severe burns. By integrating scientific rigor with scalable manufacturing processes, Vericel has established a robust market position, effectively bridging the gap between laboratory-based research and clinical application. Its commitment to improving patient outcomes through targeted biologic interventions distinguishes it as a key player in the evolving landscape of personalized medicine.
How much funding has Vericel raised?
Vericel has raised a total of $313.8M across 14 funding rounds:
Stock Offering
$12.4M
Stock Offering
$20.5M
Share Placement
$38M
Stock Offering
$9M
Private Equity
$15M
Stock Offering
$40.3M
Stock Offering
$20M
Debt
$25M
Stock Offering
$74.8M
Stock Issuance/Offering (2010): $12.4M with participation from Undisclosed
Stock Issuance/Offering (2010): $20.5M led by Undisclosed
Share Placement (2012): $38M supported by Eastern Capital
Stock Issuance/Offering (2013): $9M featuring Undisclosed
Private Equity (2014): $15M backed by Lincoln Park Capital
Stock Issuance/Offering (2014): $40.3M with participation from Undisclosed
Stock Issuance/Offering (2016): $20M led by Undisclosed
Debt (2017): $25M supported by MidCap Financial and Silicon Valley Bank
Stock Issuance/Offering (2018): $74.8M featuring Undisclosed
Key Investors in Vericel
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical early-stage support for scientific innovation.
MidCap Financial
MidCap Financial is a specialized lender that provides flexible, asset-based financing solutions tailored to the unique capital requirements of growing companies.
Silicon Valley Bank
Silicon Valley Bank is a premier financial institution focused on the innovation economy, offering comprehensive banking and investment services to high-growth technology and life science firms.
What's next for Vericel?
With the successful completion of its recent financing round, Vericel is well-positioned to scale its operational infrastructure and broaden the reach of its commercial portfolio. The company's strategic roadmap likely involves deepening its investment in research and development to explore new therapeutic indications for its existing cell therapy platforms. Furthermore, the firm is expected to prioritize the optimization of its supply chain and manufacturing efficiency, ensuring that its high-value biologic products remain accessible to a growing patient base. As Vericel continues to mature, the focus will shift toward sustaining long-term value creation through clinical excellence and the strategic expansion of its market footprint in the regenerative medicine space.
See full Vericel company page
